Collegium Pharmaceutical, Inc. (COLL) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 21, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the COLL SEC filings page.
Collegium Pharmaceutical, Inc. (COLL) reported $808.2M in revenue over the twelve months to Jun 30, 2026, up 14.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is scaling, but rising overhead absorbs much of the growth while low capital spending converts earnings into substantial cash.
Revenue increased24.0% from FY2024 to FY2025 while operating margin narrowed, despite gross margin stability. That combination points to overhead absorbing scale benefits rather than deterioration in the reported gross economics.
FY2025 operating cash flow was
Total liabilities were
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Collegium Pharmaceutical, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Collegium Pharmaceutical, Inc. has an operating margin of 23.0%, meaning the company retains $23 of operating profit per $100 of revenue. This strong profitability earns a score of 80/100, reflecting efficient cost management and pricing power. This is down from 26.9% the prior year.
Collegium Pharmaceutical, Inc.'s revenue surged 23.6% year-over-year to $780.6M, reflecting rapid business expansion. This strong growth earns a score of 79/100.
Collegium Pharmaceutical, Inc. has elevated debt relative to equity (D/E of 4.49), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 13/100, reflecting increased financial risk.
Collegium Pharmaceutical, Inc.'s current ratio of 1.57 indicates adequate short-term liquidity, earning a score of 44/100. The company can meet its near-term obligations, though with limited headroom.
Collegium Pharmaceutical, Inc. converts 42.0% of revenue into free cash flow ($327.6M). This strong cash generation earns a score of 97/100.
Collegium Pharmaceutical, Inc. earns a strong 20.9% return on equity (ROE), meaning it generates $21 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 74/100. This is down from 30.1% the prior year.
Collegium Pharmaceutical, Inc. scores 1.26, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Collegium Pharmaceutical, Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Collegium Pharmaceutical, Inc. generates $5.23 in operating cash flow ($329.3M OCF vs $63.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Collegium Pharmaceutical, Inc. earns $2.18 in operating income for every $1 of interest expense ($179.6M vs $82.3M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Collegium Pharmaceutical, Inc. generated $199.9M in revenue in Q2 2026. This represents an increase of 6.3% from the same quarter a year earlier. Against the prior quarter it is up 3.3%.
Collegium Pharmaceutical, Inc.'s EBITDA was $68.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 25.4% from the same quarter a year earlier. Against the prior quarter it is down 21.2%.
Collegium Pharmaceutical, Inc. reported -$15.1M in net income in Q2 2026. This represents a decrease of 225.6% from the same quarter a year earlier. Against the prior quarter it is down 203.8%.
Collegium Pharmaceutical, Inc. earned -$0.46 per diluted share (EPS) in Q2 2026. This represents a decrease of 235.3% from the same quarter a year earlier. Against the prior quarter it is down 215.0%.
Cash & Balance Sheet
Collegium Pharmaceutical, Inc. generated $70.8M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 2.1% from the same quarter a year earlier. Against the prior quarter it is up 24.6%.
Collegium Pharmaceutical, Inc. held $129.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Collegium Pharmaceutical, Inc.'s gross margin was 55.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 2.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.4 percentage points.
Collegium Pharmaceutical, Inc.'s operating margin was 1.8% in Q2 2026, reflecting core business profitability. This is down 16.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 14.1 percentage points.
Collegium Pharmaceutical, Inc.'s net profit margin was -7.5% in Q2 2026, showing the share of revenue converted to profit. This is down 13.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 15.0 percentage points.
Collegium Pharmaceutical, Inc.'s ROE was -4.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 10.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 9.5 percentage points.
Capital Allocation
Collegium Pharmaceutical, Inc. repurchased no shares in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Collegium Pharmaceutical, Inc. invested $496K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 663.1% from the same quarter a year earlier. Against the prior quarter it is up 83.7%.
Not reported for Q2 2026.
COLL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $199.9M+6.3% | $193.5M+8.9% | $205.4M+12.9% | $209.4M+31.4% | $188.0M+29.4% | $177.8M+22.7% | $181.9M+21.5% | $159.3M+16.5% |
| Cost of Revenue | $89.6M+12.5% | $76.3M-5.2% | $77.1M-7.9% | $80.2M+28.3% | $79.6M+46.2% | $80.4M+50.4% | $83.7M+51.8% | $62.5M+10.8% |
| Gross Profit | $110.3M+1.8% | $117.2M+20.5% | $128.4M+30.6% | $129.2M+33.4% | $108.4M+19.4% | $97.3M+6.4% | $98.3M+3.9% | $96.8M+20.5% |
| SG&A Expenses | $106.6M+44.8% | $86.3M+13.0% | $67.6M+7.2% | $67.1M+8.3% | $73.6M+69.9% | $76.4M+82.0% | $63.1M+91.5% | $62.0M+75.5% |
| Operating Income | $3.7M-89.5% | $30.9M+42.5% | $60.8M+59.4% | $62.1M+78.2% | $35.1M-26.0% | $21.7M-56.2% | $38.1M-38.2% | $34.8M-22.6% |
| EBITDA | $68.5M-25.4% | $86.8M+11.0% | $61.7M-34.8% | $63.1M-17.6% | $91.7M+10.6% | $78.3M-7.8% | $94.6M-2.6% | $76.6M-6.8% |
| Interest Expense | $19.5M-4.6% | $15.9M-23.7% | $19.3M-14.8% | $21.8M+18.3% | $20.5M+31.3% | $20.8M+19.9% | $22.7M+17.5% | $18.4M-11.4% |
| Income Tax | $1.5M-69.9% | $4.2M+502.0% | $12.1M+155.1% | $11.9M+91.0% | $5.0M-46.9% | $705K-92.1% | $4.7M-68.0% | $6.2M-23.4% |
| Net Income | -$15.1M-225.6% | $14.5M+499.8% | $17.0M+35.3% | $31.5M+237.5% | $12.0M-38.9% | $2.4M-91.3% | $12.5M-60.8% | $9.3M-54.8% |
| EPS (Basic) | -$0.46-221.1% | $0.45+462.5% | $0.54+38.5% | $1.00+244.8% | $0.38-36.7% | $0.08-90.7% | $0.39-60.6% | $0.29-52.5% |
| EPS (Diluted) | -$0.46-235.3% | $0.40+471.4% | $0.46+27.8% | $0.84+211.1% | $0.34-34.6% | $0.07-90.1% | $0.36-56.1% | $0.27-49.1% |
| Diluted Shares (Avg) | 32M-16.9% | 40M+22.0% | 40M-0.1% | 39M-1.8% | 39M-3.2% | 33M-20.7% | 40M-2.8% | 40M-4.5% |
Not reported in any period shown, so not listed: R&D Expenses.
COLL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.1B+34.1% | $1.7B+1.3% | $1.7B-0.4% | $1.6B-1.7% | $1.6B+51.2% | $1.6B+46.4% | $1.7B+45.5% | $1.6B+38.9% |
| Current Assets | $608.0M+10.7% | $745.7M+41.3% | $691.4M+43.4% | $613.9M+38.3% | $549.2M+7.6% | $527.6M-2.2% | $482.3M-10.3% | $443.8M-17.4% |
| Cash & Equivalents | $129.5M+10.3% | $268.6M+179.3% | $231.3M+227.7% | $150.1M+285.3% | $117.3M-32.1% | $96.2M-57.9% | $70.6M-70.5% | $39.0M-84.9% |
| Short-Term Investments | $0-100.0% | $153.1M+50.7% | $155.4M+68.6% | $135.8M+67.6% | $104.8M+6.1% | $101.6M+13.6% | $92.2M+28.8% | $81.0M+76.0% |
| Inventory | $113.3M+196.9% | $42.7M+14.8% | $40.9M+15.1% | $38.1M+0.1% | $38.1M+36.9% | $37.2M+19.0% | $35.6M+10.0% | $38.0M+11.4% |
| Accounts Receivable | $285.1M+33.8% | $228.8M0.0% | $211.3M-7.5% | $233.9M+2.4% | $213.0M+15.9% | $228.7M+30.9% | $228.5M+27.3% | $228.5M+25.6% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $190.2M+28.6% | $145.9M-3.2% | $145.9M-10.1% | $145.9M0.0% | $147.9M+10.5% | $150.8M+12.6% | $162.3M+21.3% | $146.0M+9.0% |
| Total Liabilities | $1.8B+34.1% | $1.3B-4.1% | $1.4B-5.5% | $1.3B-4.9% | $1.4B+62.6% | $1.4B+56.6% | $1.4B+51.4% | $1.4B+40.3% |
| Current Liabilities | $589.9M+27.0% | $435.0M-10.6% | $440.0M-13.6% | $452.9M-1.4% | $464.6M+0.6% | $486.7M+9.0% | $509.5M+11.3% | $459.4M-1.1% |
| Non-Current Liabilities | $1.2B+37.8% | $904.6M-0.6% | $915.1M-1.1% | $879.6M-6.6% | $895.8M+138.8% | $910.2M+104.3% | $925.2M+88.8% | $941.4M+76.3% |
| Total Equity | $311.9M+34.3% | $312.4M+33.3% | $301.7M+31.8% | $274.8M+17.3% | $232.2M+7.2% | $234.4M+5.5% | $228.8M+17.1% | $234.3M+31.0% |
| Retained Earnings | -$101.7M+32.0% | -$86.6M+46.4% | -$101.1M+38.3% | -$118.1M+33.1% | -$149.6M+19.5% | -$161.6M+21.4% | -$164.0M+29.7% | -$176.5M+33.4% |
Not reported in any period shown, so not listed: Long-Term Debt.
COLL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $71.3M-1.5% | $57.1M+3.1% | $123.0M+45.4% | $78.4M+971.6% | $72.4M+7.5% | $55.4M-10.6% | $84.6M+15.4% | -$9.0M-112.2% |
| Depreciation & Amortization | $64.8M+14.4% | $55.9M-1.1% | $923K-98.4% | $1.0M-97.5% | $56.6M+59.6% | $56.6M+59.6% | $56.5M+59.4% | $41.7M+12.4% |
| Stock-Based Compensation | N/A | $10.9M-5.6% | N/A | N/A | N/A | $11.5M+54.2% | N/A | $7.3M+4.1% |
| Capital Expenditures | $496K+663.1% | $270K-66.2% | $689K+20.9% | $188K-23.0% | $65K-75.9% | $798K+40.5% | $570K+247.6% | $244K+275.4% |
| Free Cash Flow | $70.8M-2.1% | $56.8M+4.1% | $122.4M+45.5% | $78.3M+946.6% | $72.4M+7.8% | $54.6M-11.0% | $84.1M+14.9% | -$9.2M-112.5% |
| Investing Cash Flow | -$502.6M-17141.5% | $1.6M+116.8% | -$20.1M-70.6% | -$30.9M+87.6% | -$2.9M+67.3% | -$9.7M+46.6% | -$11.8M+53.1% | -$249.0M-6413.9% |
| Financing Cash Flow | $292.1M+703.9% | -$21.3M+15.4% | -$21.8M+47.1% | -$14.8M-109.9% | -$48.4M+57.6% | -$25.2M+53.4% | -$41.3M+39.1% | $149.0M+256.2% |
| Share Buybacks | $0-100.0% | N/A | $0-100.0% | $0 | $25.1M | N/A | $25.0M+0.1% | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
COLL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-K | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.2%-2.5pp | 60.6%+5.8pp | 62.5%+8.5pp | 61.7%+0.9pp | 57.6%-4.9pp | 54.8%-8.4pp | 54.0%-9.2pp | 60.8%+2.0pp |
| Operating Margin | 1.8%-16.8pp | 16.0%+3.8pp | 29.6%+8.6pp | 29.7%+7.8pp | 18.7%-14.0pp | 12.2%-21.9pp | 20.9%-20.3pp | 21.9%-11.1pp |
| Net Margin | -7.5%-13.9pp | 7.5%+6.1pp | 8.3%+1.4pp | 15.0%+9.2pp | 6.4%-7.1pp | 1.4%-17.8pp | 6.9%-14.4pp | 5.9%-9.2pp |
| Return on Equity | -4.8%-10.0pp | 4.6%+3.6pp | 5.6%+0.1pp | 11.5%+7.5pp | 5.2%-3.9pp | 1.0%-11.4pp | 5.5%-10.9pp | 4.0%-7.6pp |
| Return on Assets | -0.7%-1.4pp | 0.9%+0.7pp | 1.0%+0.3pp | 2.0%+1.4pp | 0.8%-1.1pp | 0.1%-2.3pp | 0.8%-2.0pp | 0.6%-1.2pp |
| Current Ratio | 1.03-0.2x | 1.71+0.6x | 1.57+0.6x | 1.36+0.4x | 1.18+0.1x | 1.08-0.1x | 0.95-0.2x | 0.97-0.2x |
| Debt-to-Equity | 5.850.0x | 4.29-1.7x | 4.49-1.8x | 4.85-1.1x | 5.86+2.0x | 5.96+1.9x | 6.27+1.4x | 5.98+0.4x |
| Asset Turnover | 0.090.0x | 0.120.0x | 0.120.0x | 0.130.0x | 0.120.0x | 0.110.0x | 0.110.0x | 0.100.0x |
| FCF Margin | 35.4%-3.1pp | 29.4%-1.3pp | 59.6%+13.4pp | 37.4%+43.2pp | 38.5%-7.7pp | 30.7%-11.6pp | 46.2%-2.7pp | -5.8%-59.9pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc. COLL | FY2025 | $780.6M | $63.0M | 8.1% | $756.3M | 65/100 |
| Pacira BioSciences, Inc. PCRX | FY2025 | $726.4M | $7.0M | 1.0% | $1.5B | 53/100 |
| Dynavax Technologies Corporation DVAX | FY2024 | $277.2M | $27.3M | 9.8% | $1.8B | 54/100 |
| Harrow, Inc. HROW | FY2025 | $272.3M | -$5.1M | -1.9% | $1.1B | 52/100 |
| Amphastar Pharmaceuticals, Inc. AMPH | FY2025 | $719.9M | $98.1M | 13.6% | $1.1B | 69/100 |
Where Collegium Pharmaceutical, Inc. Ranks
Frequently Asked Questions
What is Collegium Pharmaceutical, Inc.'s annual revenue?
Collegium Pharmaceutical, Inc. (COLL) reported $780.6M in total revenue for fiscal year 2025. This represents a 23.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Collegium Pharmaceutical, Inc.'s revenue growing?
Collegium Pharmaceutical, Inc. (COLL) revenue grew by 23.6% year-over-year, from $631.4M to $780.6M in fiscal year 2025.
Is Collegium Pharmaceutical, Inc. profitable?
Yes, Collegium Pharmaceutical, Inc. (COLL) reported a net income of $63.0M in fiscal year 2025, with a net profit margin of 8.1%.
What is Collegium Pharmaceutical, Inc.'s EBITDA?
Collegium Pharmaceutical, Inc. (COLL) had EBITDA of $405.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Collegium Pharmaceutical, Inc.'s gross margin?
Collegium Pharmaceutical, Inc. (COLL) had a gross margin of 59.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Collegium Pharmaceutical, Inc.'s operating margin?
Collegium Pharmaceutical, Inc. (COLL) had an operating margin of 23.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Collegium Pharmaceutical, Inc.'s net profit margin?
Collegium Pharmaceutical, Inc. (COLL) had a net profit margin of 8.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Collegium Pharmaceutical, Inc.'s return on equity (ROE)?
Collegium Pharmaceutical, Inc. (COLL) has a return on equity of 20.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Collegium Pharmaceutical, Inc.'s free cash flow?
Collegium Pharmaceutical, Inc. (COLL) generated $327.6M in free cash flow during fiscal year 2025. This represents a 61.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Collegium Pharmaceutical, Inc.'s operating cash flow?
Collegium Pharmaceutical, Inc. (COLL) generated $329.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Collegium Pharmaceutical, Inc.'s total assets?
Collegium Pharmaceutical, Inc. (COLL) had $1.7B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Collegium Pharmaceutical, Inc.'s capital expenditures?
Collegium Pharmaceutical, Inc. (COLL) invested $1.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Collegium Pharmaceutical, Inc.'s current ratio?
Collegium Pharmaceutical, Inc. (COLL) had a current ratio of 1.57 as of fiscal year 2025, which is generally considered healthy.
What is Collegium Pharmaceutical, Inc.'s debt-to-equity ratio?
Collegium Pharmaceutical, Inc. (COLL) had a debt-to-equity ratio of 4.49 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Collegium Pharmaceutical, Inc.'s return on assets (ROA)?
Collegium Pharmaceutical, Inc. (COLL) had a return on assets of 3.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Collegium Pharmaceutical, Inc.'s P/E ratio?
Collegium Pharmaceutical, Inc. (COLL) trades at 15.8x earnings, its market capitalization divided by net income of $47.9M net income, trailing 12 months to June 30, 2026. The market capitalization is $756.3M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Collegium Pharmaceutical, Inc.'s price-to-sales ratio?
Collegium Pharmaceutical, Inc. (COLL) trades at 0.9x sales, its market capitalization divided by revenue of $808.2M revenue, trailing 12 months to June 30, 2026. The market capitalization is $756.3M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Collegium Pharmaceutical, Inc.'s Altman Z-Score?
Collegium Pharmaceutical, Inc. (COLL) has an Altman Z-Score of 1.26, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Collegium Pharmaceutical, Inc.'s Piotroski F-Score?
Collegium Pharmaceutical, Inc. (COLL) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Collegium Pharmaceutical, Inc.'s earnings high quality?
Collegium Pharmaceutical, Inc. (COLL) has an earnings quality ratio of 5.23x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Collegium Pharmaceutical, Inc. cover its interest payments?
Collegium Pharmaceutical, Inc. (COLL) has an interest coverage ratio of 2.18x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Collegium Pharmaceutical, Inc.?
Collegium Pharmaceutical, Inc. (COLL) scores 65 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.